IDEX Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IEX research report →
Range $245 – $280
Price Chart
About the company
IDEX Corporation is an international enterprise specializing in engineered solutions across diverse sectors. The company operates through three primary business units: Fluid & Metering Technologies (FMT), Health & Science Technologies (HST), and Fire & Safety/Diversified Products (FSDP). The FMT division is responsible for the design, production, and distribution of a range of fluid-handling equipment, including positive displacement pumps, flow meters, and injectors, alongside offering flow monitoring and related services.
- CEO
- Eric D. Ashleman
- IPO
- 1989
- Employees
- 8,700
- HQ
- Northbrook, IL, US
AI snapshot
Six angles, distilled from the data.
The stock remains in a constructive long-term uptrend, trading above its 200-day moving average and well above the 52-week low. It is still below the 52-week high, so the regime is bullish but not stretched into a breakout phase.
Street sentiment stays positive: 15 buys, 14 holds, and no sells, with a Buy consensus and an average target of $266.13 versus the current price. Recent calls mostly nudged targets higher, including multiple raises on October 29, which reinforces a steady but not euphoric setup.
The earnings pattern is strong: IEX has beaten estimates in all 8 of the last 8 quarters, including a 4.5% beat in the latest report. Next-year EPS estimates point to $9.83 from $7.20 TTM, so shareholders should watch whether margin discipline keeps converting revenue growth into earnings growth.
Recent activity leans to net selling, but most of the volume is automatic vesting, in-kind, or award-related flow rather than discretionary conviction. The clearest signal is CEO Eric Ashleman’s May sales, while the newer officer transactions look more like routine compensation mechanics than a directional trade.
Profitability is solid, with a 44.9% gross margin, 21.4% operating margin, and 14.7% net margin. Growth is healthy too, with revenue up 8.3% and earnings up 14.7% year over year, while free cash flow reached $744 million and $10.13 per share in fiscal 2025.
IEX looks like a quality industrial compounder rather than a deep-value name, supported by strong margins and consistent earnings beats. The stock trades at 27.68x earnings, a premium that fits its above-average profitability and steady execution.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $16.13B
- P/E
- 31.16
- Fwd P/E
- 24.54
- PEG
- 2.19
- P/S
- 4.52
- P/B
- 4.13
- EV/EBITDA
- 18.03
- Div Yield
- 1.29%
- Gross Margin
- 44.87%
- Op Margin
- 20.95%
- Net Margin
- 14.65%
- ROE
- 13.31%
- ROIC
- 9.34%
Latest fiscal year · YoY change
- Revenue
- $3.46B+5.8%
- Gross Profit
- $1.54B+1.5%
- Op Income
- $720.00M
- Net Income
- $483.20M-4.3%
- EPS
- $6.41-3.9%
- OCF Growth
- +1.8%
- FCF Growth
- +2.3%
- 52W High
- $243.80
- 52W Low
- $162.90
- 50D MA
- $231.71
- 200D MA
- $218.71
- Beta
- 0.95
- RSI (14)
- 36
- Avg Volume
- 676.54K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
IDEXX said Q3 beat expectations across sales, margins, and EPS, and it raised full-year 2026 guidance on continued strength in advantaged markets and improving industrial demand.· October 28, 2026
- Organic sales grew 8% in Q3; adjusted EPS rose 15% to $2.33 and adjusted EBITDA margin expanded 50 bps to 27.8%.
- Orders were a standout at nearly $1 billion, up 13% organically, with growth in all three segments and book-to-bill above 1x.
- Management raised full-year 2026 guidance for organic growth to 6.5% to 6.8% and adjusted EPS to $8.91 to $8.96.
- HST continued to lead, with organic sales up 13% and orders up 21%; FMT and FSDP also contributed, and industrial demand broadened.
- Free cash flow was $214 million, up 14%, with 124% conversion; leverage improved to 1.8x and the company kept buying back shares.
Q3 organic revenue grew 8%, above guidance of 5% to 7%. Adjusted EBITDA margin was 27.8%, above the 27% to 27.5% range, and adjusted EPS was $2.33, above the $2.20 to $2.25 range. Adjusted gross margin expanded 70 bps to 45.2%, and free cash flow was $214 million, up 14%, with 124% conversion. Orders totaled nearly $1 billion, up 13% organically. For full-year 2026, management raised organic growth guidance to 6.5% to 6.8% from 5% to 6%, tightened adjusted EBITDA margin to 27.1% to 27.3%, and raised adjusted EPS to $8.91 to $8.96 from $8.70 to $8.85. It still expects about $110 million of capex and at least 100% free cash flow conversion.
Eric Ashleman framed the quarter as validation of the company’s acquisition and portfolio strategy, saying the businesses bought over the last five years are now driving growth and margin expansion. He emphasized “tunability” across integrated platforms as a key advantage, describing how IDEXX can reallocate capabilities into faster-growing markets like data centers, semiconductors, space and defense, and water. His tone was confident and constructive, with repeated emphasis on durability, runway, and the company’s ability to expand both growth and profitability.
Sean Gillen focused on the numbers behind the beat: organic sales up 8%, adjusted EBITDA margin at 27.8%, adjusted EPS at $2.33, and gross margin at 45.2%. He highlighted strong order growth across HST, FMT, and FSDP, positive price/cost, and free cash flow of $214 million with 124% conversion. On capital allocation, he said gross leverage improved to 1.8x, the company paid $54 million in dividends, repurchased $75 million of shares in the quarter, and plans to maintain repurchases around $75 million per quarter through 2026, with flexibility above that depending on leverage and M&A.
Analysts pressed on what is broadening beyond the core advantaged markets, and management said they are seeing modest but consistent improvement in smaller order rates, plus better signs in ag and energy, while chemicals remains fatigued. Questions on HST and data center timing were answered with the point that data center orders remain lumpy and unpredictable, but backlog and visibility support continued growth. On M&A, management said activity is high and the pipeline remains active, but valuations are still robust, so they will stay disciplined. Management also said pricing is around 2% of top line in 2026 and should continue to run above cost.
The bullish case is that IDEXX is converting its acquired portfolio into durable growth, with advantaged markets still strong and industrial demand broadening. Management sounded confident that orders, backlog, pricing, and operating leverage can support continued double-digit EPS growth and high-30s to 40% incremental margins.
The main risks discussed were lumpy data center order timing, still-fatigued chemicals, ag, and energy businesses, and the possibility that some of the faster-growing markets could eventually face capacity or demand normalization. Management also noted that fourth-quarter margins will step down sequentially because of fewer production days and planned maintenance shutdowns, and that M&A valuations remain elevated.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.7%
- Shares Outstanding
- 73.45M
- Float Shares
- 73.27M
of shares held by institutions
709 13F filers
Buy/sell ratio 0.17. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for IEX, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Lisa C. McClainHouse · MI09 | Buy | Oct 30, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Oct 30, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Oct 31, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Aug 4, 25 | Filing → |
| Jefferson ShreveHouse · IN06 | Sell | Mar 31, 25 | Filing → |
| Jefferson ShreveHouse · IN06 | Sell | Feb 24, 25 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Sell | Apr 3, 24 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Aug 3, 23 | Filing → |
| Ro KhannaHouse · CA17 | Sell | May 19, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 6, 22 | Filing → |
| Ro KhannaHouse · CA17 | Sell | May 10, 22 | Filing → |
| Ro KhannaHouse · CA17 | Buy | May 5, 22 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Feb 17, 22 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Feb 14, 22 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 8.99M | ▼ 100.38K |
| Blackrock, Inc. | 5.70M | ▼ 31.51K |
| Vanguard Capital Management LLC | 4.82M | ▼ 25.83K |
| Vanguard Portfolio Management LLC | 3.71M | ▼ 21.89K |
| State Street Corp | 3.37M | ▲ 57.25K |
| Primecap Management Co | 3.30M | ▼ 3.86K |
| Morgan Stanley | 2.70M | ▼ 118.60K |
| Geode Capital Management, LLC | 2.14M | ▲ 40.19K |
| Invesco Ltd. | 1.82M | ▲ 317.24K |
| Millennium Management LLC | 1.78M | ▼ 593.90K |
| Wellington Management Group Llp | 1.76M | ▲ 615.82K |
| Amundi | 1.42M | ▼ 38.65K |
Held by 1,589 ETFs
Biggest fund positions in IEX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 16, 26 | Tereso Tara M. | other | 290 |
| Sep 16, 26 | Simmons William L. | other | 218 |
| Sep 11, 26 | Tereso Tara M. | other | 138 |
| Aug 29, 26 | Lausas Allison S | other | 645 |
| Aug 12, 26 | Anderson Lisa M | other | 385 |
| Aug 12, 26 | Anderson Lisa M | sell | 385 |
| Aug 12, 26 | Anderson Lisa M | other | 385 |
| May 11, 26 | ASHLEMAN ERIC D | other | 15,385 |
| May 11, 26 | ASHLEMAN ERIC D | sell | 10,470 |
| May 11, 26 | ASHLEMAN ERIC D | sell | 4,915 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IEX coverage
Recent articles, reports, and earnings notes.

IDEX Corporation (IEX): Data Center and Semiconductor Growth
IDEX is benefiting from strong orders, record Health & Science Technologies sales and exposure to data centers and semiconductors. The stock is rated Buy despite a premium valuation, supported by improving guidance and durable cash generation.

IDEX Corporation (IEX) gains on deep Q3 earnings analysis
IDEX Corporation (IEX) gains after a broad Q3 beat, with adjusted EPS and revenue topping estimates, orders strengthening across all segments, and margins improving. The deeper story is the raised 2026 outlook, record Health and Science orders, and continued momentum in data center, semiconductor, and defense markets.

IDEX Corporation (IEX) slips despite earnings beats
IDEX Corporation (IEX) slips 0.2% even after posting earnings beats, as investors weigh the latest results against broader market sentiment and outlook.
Want a deeper read on IEX?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
IDEX: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 17
IDEX Corporation (IEX) Presents at RBC Global Industrials Conference 2026 Transcript
seekingalpha.com · Nov 16
4 Industrial Manufacturing Stocks to Gain on Robust Industry Trends
zacks.com · Nov 13
IDEX Corporation Declares Regular Quarterly Cash Dividend
businesswire.com · Nov 11
IDEX Corporation (IEX) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 28
IDEX Q3 Earnings Beat Estimates on HST Strength, View Raised
zacks.com · Oct 28
Compared to Estimates, Idex (IEX) Q3 Earnings: A Look at Key Metrics
zacks.com · Oct 28
Idex (IEX) Q3 Earnings and Revenues Beat Estimates
zacks.com · Oct 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 19, 2026 · Live quote · Not investment advice